<i>NOTCH1</i> Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.

Furthermore, progression-free survival showed a trend of improvement for tislelizumab versus ICC in patients with NOTCH1 mutations (HR, 0.71 [95% CI, 0.37 to 1.37]), but not WT NOTCH1 (HR, 0.94 [95% CI, 0.66 to 1.34]; extended data given in Fig 1 C).

also in 53,322 other papers